# DeFi (NCT03785964)

> Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03785964
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
- Conditions: Desmoid Tumor; Aggressive Fibromatosis
- Interventions: Nirogacestat oral tablet; Placebo Oral Tablet
- Enrollment: 142
- Primary outcome: Progression Free Survival (PFS) Defined as the Time From Randomization Until Date of Assessment of Progression or Death by Any Cause.

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- YouTube: 20
- X threads: 15
- Podcasts: 14
- Bluesky threads: 1

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=defi-nct03785964

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03785964", "email": "<work email>"}; the inbox owner confirms by the emailed link.